Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12

REFERENCES

1. 1.↵
   1. Arnett FC,
   2. Edworthy SM,
   3. Bloch DA,
   4. McShane DJ,
   5. Fries JF,
   6. Cooper NS,
   7. et al.

   The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Aletaha D,
   2. Neogi T,
   3. Silman AJ,
   4. Funovits J,
   5. Felson DT,
   6. Bingham CO III,
   7. et al.

   Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580–8.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. van Tuyl LH,
   2. Lems WF,
   3. Voskuyl AE,
   4. Kerstens PJ,
   5. Garnero P,
   6. Dijkmans BA,
   7. et al.

   Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008;67:1574–7.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Wells GA,
   2. Boers M,
   3. Shea B,
   4. Brooks PM,
   5. Simon LS,
   6. Strand CV,
   7. et al.

   Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016–24.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Smolen JS,
   2. Aletaha D,
   3. Bijlsma JW,
   4. Breedveld FC,
   5. Boumpas D,
   6. Burmester G

   . Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. van Tuyl LH,
   2. Vlad SC,
   3. Felson DT,
   4. Wells G,
   5. Boers M

   . Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum 2009;61:704–10.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Felson DT,
   2. Smolen J,
   3. Wells GA,
   4. Zhang B,
   5. van Tuyl LH,
   6. Funovits J,
   7. et al.

   American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Boers M,
   2. Tugwell P,
   3. Felson DT,
   4. van Riel PLCM,
   5. Kirwan JR,
   6. Edmonds JP,
   7. et al.

   World Health Organization and and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl. 1994 Sept;41:86–9.

   OpenUrlPubMed
9. 9.↵
   1. Felson DT,
   2. Anderson JJ,
   3. Boers M,
   4. Bombardier C,
   5. Chernoff M,
   6. Fried B,
   7. et al.

   The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729–40.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Kirwan J,
    2. Minnock P,
    3. Adebajo A,
    4. Bresnihan B,
    5. Choy E,
    6. De Witt M,
    7. et al.

    Patient Perspective Workshop: fatigue as a recommended patient-centred outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174–7.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. van Tuyl LH,
    2. Smolen JS,
    3. Wells GA,
    4. Scholte-Voshaar M,
    5. Hoogland W,
    6. Boers M

    . Patient perspective on remission in rheumatoid arthritis. J Rheumatol 2011;38:1735–8.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. van Tuyl LH,
    2. Hewlett S,
    3. Stamm T,
    4. Davis B,
    5. Flurey C,
    6. Hoogland W,
    7. et al.

    “Back to being normal”: the patient perspective on remission in rheumatoid arthritis. Ann Rheum Dis 2013;72 Suppl 3:562.

    OpenUrl
13. 13.↵
    1. Gossec L,
    2. Dougados M,
    3. Rincheval N,
    4. Balanescu A,
    5. Boumpas DT,
    6. Canadelo S,
    7. et al.

    Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009;68:1680–5.

    OpenUrlAbstract/FREE Full Text
14. 14.
    1. Boers M,
    2. Kirwan JR,
    3. Wells G,
    4. Beaton D,
    5. Gossec L,
    6. d’Agostino MA,
    7. et al.

    Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745–53.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. van Tuyl LH,
    2. Boers M

    . Patient’s global assessment of disease activity: what are we measuring? Arthritis Rheum 2012;64:2811–3.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Studenic P,
    2. Smolen JS,
    3. Aletaha D

    . Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis 2012;71:1702–5.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Masri KR,
    2. Shaver TS,
    3. Shahouri SH,
    4. Wang S,
    5. Anderson JD,
    6. Busch RE,
    7. et al.

    Validity and reliability problems with patient global as a component of the ACR/EULAR remission criteria as used in clinical practice. J Rheumatol 2012;39:1139–45.

    OpenUrlAbstract/FREE Full Text